As part of the collaboration, MRI Interventions will contribute its ClearPoint neurological navigation system and SmartFlow neuroventricular cannula, an MRI-compatible injection and aspiration cannula for use in the brain. SmartFlow is compatible with ClearPoint.
The products will be used in Voyager Therapeutics' planned phase II/III program for its aromatic L-amino acid decarboxylase (AADC) gene therapy, known as VY-AADC, for Parkinson's disease.
In addition, the companies plan to jointly develop new minimally invasive neurosurgical devices using real-time MRI guidance, including new hardware, software, and cannulas for other Voyager Therapeutics gene therapies.
Copyright © 2018 AuntMinnie.com